Gyre Therapeutics Inc

GYRE

Equity

ISIN null / Valor 130270397

NASDAQ (2025-11-17)

USD 8.02+0.38%

Gyre Therapeutics Inc
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Gyre Therapeutics Inc, based in San Diego, CA, is a biopharmaceutical entity engaged in the development and commercialization of innovative treatments for chronic liver diseases, with a primary focus on Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis, formerly known as Nonalcoholic Steatohepatitis or NASH) in the United States. The company's flagship product, Hydronidone (F351), is under investigation in the U.S. for its efficacy in treating liver fibrosis across a spectrum of chronic liver conditions, supported by an active Investigational New Drug (IND) application. This application is bolstered by a comprehensive nonclinical program compliant with Good Laboratory Practice (GLP) and Phase 1 clinical trial data on the pharmacokinetics, safety, and tolerability of Hydronidone. The decision to target the MASH indication in the U.S. is informed by promising results from mechanistic studies in MASH rodent models and a Phase 2 clinical study in China for chronic Hepatitis-B induced liver fibrosis, which demonstrated safety and efficacy. Furthermore, Gyre is expanding its portfolio in China through Beijing Continent, a subsidiary with a controlling interest, advancing a diverse pipeline that includes pirfenidone—an approved treatment for Idiopathic Pulmonary Fibrosis in China—among other investigational drugs for various conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Leadership Transition

Ping Zhang has been appointed as the interim CEO as Dr. Han Ying transitions to the role of Senior Vice President, Science. This strategic move aims to bolster Gyre’s global expansion and scientific innovation.

Revenue and Earnings

For the three months ended June 30, 2025, Gyre reported revenues of $26.8 million, a slight increase from $25.2 million in the same period last year. GAAP basic EPS stood at $0.00 for the quarter, up from $0.04 for the six months ended June 30, 2025.

Pipeline Progress

Gyre’s Hydronidone (F351) achieved statistically significant fibrosis regression in its Phase 3 trial for CHB-associated liver fibrosis. Additionally, the company successfully launched Etorel in the PRC and initiated its first Phase 1 trial for F230 targeting PAH.

Cash Position

As of June 30, 2025, Gyre held a robust cash position of $75.9 million, supported by proceeds from a recent public offering and increased capital contributions from BJContinent Pharmaceuticals Limited.

Summarized from source with an LLMView Source

Key figures

-38.9%1Y

-3.10%3Y

-90.8%5Y

Performance

94.1%1Y

119%3Y

133%5Y

Volatility